SavedAdd your journal

Journals / ARTEMİS / 2004 / Cilt: 5 - Sayı: 3

Evaluation of the efficacy of raloxifene and risedronate on bone mineral density and lipid profile

Postmenopozal hastalarda raloksifen ve risedronatın kemik mineral yoğunluğu ve lipit profili üzerindeki etkinliklerinin değerlendirilmesi

Oktay KADAYIFÇI
Devrim ERTUNÇ
Ali Ulvi HAKVERDİ
Ekrem TOK
Saffet DİLEK
Journal
ARTEMİS
Pages
224–229
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: At the end of six months, it was observed that risedronate increased the bone mineral density at lumbar spine than did raloxifene (P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare the efficacy of raloxifene and risedronate monotherapies on bone mineral density and serum lipid profile.
📊
Key Findings & Data:Materials and Methods: 100 healthy postmenopausal women with intact uterus and ovaries, who had their last menstrual period at least three years ago and who had no obvious vasomotor symptoms were included in the study.
💡
Conclusion & Impact:Results: At the end of six months, it was observed that risedronate increased the bone mineral density at lumbar spine than did raloxifene (P
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To compare the efficacy of raloxifene and risedronate monotherapies on bone mineral density and serum lipid profile. Materials and Methods: 100 healthy postmenopausal women with intact uterus and ovaries, who had their last menstrual period at least three years ago and who had no obvious vasomotor symptoms were included in the study. The half of the pa¬tients was treated with risedronate 5 mg/day and the other half with raloxifene 60 mg/day for six months. The groups were compared according to percent changes of bone mineral density and serum lipid profile at the end of the treatment period. Results: At the end of six months, it was observed that risedronate increased the bone mineral density at lumbar spine than did raloxifene (P

Özet

Amaç: Raloksifen ve risedronat monoterapilerinin, kemik mineral yoğunluğu ve serum lipit profili üzerindeki etkinliklerinin karşılaştırılması. Materyal ve Metot: Çalışmaya son âdet tarihinden itibaren en az üç yıl geçmiş, belirgin vazomotor semptomları olmayan, uterus ve överleri intakt, sağlıklı 100 postmenopozal kadın dahil edildi. 6 ay boyunca hastaların yarısına risedronat 5 mg/gün, yarısına ise raloksifen 60 mg/gün uygulandı. Gruplar tedavi sonrası, kemik mineral yoğunluğu ve serum lipit profili yüzde değişimleri açısından karşılaştırıldı. Sonuçlar: 6 aylık tedavi sonrasında risedronatın, lumbar vertebra kemik mineral yoğunluğunu raloksifenden daha fazla artırdığını (P

🔖

Cite This Article

KADAYIFÇI, O., ERTUNÇ, D., HAKVERDİ, A. U., TOK, E., DİLEK, S. (2022). Evaluation of the efficacy of raloxifene and risedronate on bone mineral density and lipid profile. ARTEMİS, Cilt: 5 - Sayı: 3, 224–229. https://ajindex.com/articles/449464

References (12)

  1. Peck WA, Burckhardt P, Christiansen C, Fleisch HA, Genant HK, Gennari C, Martin TJ, Martini L, Morita R, Ogata E, Rapado A, Shulman LE, Stern PH, Young RTT. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50
  2. Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis. JAMA 1941;116:2465-74
  3. Riffee JM. Osteoporosis: prevention and management. Ann Pharm 1992;32:665-76
  4. Ettinger B. Optimal use of postmenopausal hormone replacement. Obstet Gynecol 1988;72:31S-6S
  5. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33
  6. Beral V; Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 2003;362:419- 27
  7. Erben RG, Mosekilde L, Thomsen JS, Weber K, Stahr K, Leyshon A, Smith SY, Phipps R. Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3. J Bone Miner Res 2002;17:1498-511
  8. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998;83:396-402
  9. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMDMN Study Group. J Clin Endocrinol Metab 2000;85:1895-900
  10. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
  11. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91
  12. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical b